Life Science Connect Editorial Director, Dan Schell, works with a talented and passionate group of editors. Each week, he sits down with them to discuss their pressing coverage areas, latest travels, and interesting interviews from within the life sciences landscape. His rotating cast of contributors includes Life Science Connect editors Rob Wright, Ed Miseta, Louis Garguilo, Anna Rose Welch, Erin Harris, and Matt Pillar.
Special Edition #10: What Does It Take To Start A Biopharmaceutical Company?
Considering many Life Science Leader readers daydream of starting and leading their own biopharmaceutical company someday, we thought it would be informative to host an executive virtual roundtable with three biopharmaceutical company CEOs who have done just that.
Special Edition #11: Making Diversity & Inclusion A Best Business Practice
Diversity & inclusion is — and has been — an important issue for the biopharmaceutical industry. As such, we thought it would be worthwhile to gain some perspective.
Special Edition #9: Pitching And Fundraising In The New Norm
Fundraising used to always be done in person. But then COVID hit. From those first virtual pitches that may have been just a little bit “wonky,” biopharma execs have actually become quite proficient at the process and the platforms. Three biopharma execs share some best practices of the virtual pitch.
029: The Effects Of Politics On Pharma
According to Outsourced Pharma Chief Editor, Louis Garguilo, “politics has never played a bigger role in our (global) biopharma industry.” In this episode, we talk with Louis about three of his recent editorials that touch on this subject while also discussing the current IP debate in pharma and the origins of the coronavirus.
Special Edition #8: Preparing For A Virtual J.P. Morgan Healthcare Conference (JPM)
We thought it would be interesting to have a discussion with three biopharmaceutical executives about how they are preparing for this unique 2021 JPM and how those preparations are different than what they’ve done in the past.
Special Edition #7: Manufacturing And Supply Chain Risk Mitigation Strategies Amidst COVID-19
We sat down with three biopharmaceutical industry executives to discuss some of the thinking and actions taken to mitigate risk to their companies’ manufacturing and supply chains amidst a pandemic.